A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Non-small Cell Lung Cancer

In brief

The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with locally advanced and metastatic Non Small Cell Lung Cancer (NSCLC).

Key facts

Study ID

NCT00113516

Run by

Pfizer

People needed

84

Starts

2005-09-01

Expected to finish

2009-03-01

Last updated by the study team

2010-05-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically proven NSCLC
• Stage IIIB (locally advanced with malignant effusion) or Stage IV disease
• No prior therapy for NSCLC
• Evidence of unidimensionally measurable disease

You may not qualify if…

• Previous treatment with systemic chemotherapy for lung cancer
• History of or known brain metastases
• NCI CTCAE Grade 3 hemorrhage within 4 weeks of starting study treatment
• Evidence of hemoptysis within 4 weeks of starting study treatment
• Serious acute or chronic illness or recent history of significant cardiac abnormality
• Previous treatment with anti-angiogenesis agents including thalidomide, or inhibitors of EGFR and PDGFR

Where it is running

• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Newark, Delaware, United States
• Pfizer Investigational Site — Newark, Delaware, United States
• Pfizer Investigational Site — Wilmington, Delaware, United States
• Pfizer Investigational Site — Maywood, Illinois, United States
• Pfizer Investigational Site — Jeffersonville, Indiana, United States
• Pfizer Investigational Site — Louisville, Kentucky, United States
• Pfizer Investigational Site — Louisville, Kentucky, United States
• Pfizer Investigational Site — Louisville, Kentucky, United States
• Pfizer Investigational Site — Shelbyville, Kentucky, United States
• Pfizer Investigational Site — Hershey, Pennsylvania, United States
• Pfizer Investigational Site — Franklin, Tennessee, United States
• Pfizer Investigational Site — Gallatin, Tennessee, United States
• Pfizer Investigational Site — Hermitage, Tennessee, United States
• Pfizer Investigational Site — Lebanon, Tennessee, United States
• Pfizer Investigational Site — Murfreesboro, Tennessee, United States
• Pfizer Investigational Site — Nashville, Tennessee, United States
• Pfizer Investigational Site — Nashville, Tennessee, United States
• Pfizer Investigational Site — Nashville, Tennessee, United States
• Pfizer Investigational Site — Nashville, Tennessee, United States
• Pfizer Investigational Site — Nashville, Tennessee, United States
• Pfizer Investigational Site — Smyrna, Tennessee, United States
• Pfizer Investigational Site — Burleson, Texas, United States
• Pfizer Investigational Site — Cleburne, Texas, United States
• Pfizer Investigational Site — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.